EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 3.0

Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab

Lang Yu, Gang Hu, Quanhong Zhang iD, Yue Zhu iD, Liuqing Chen, Jinbo Chen iD

Clinical, Cosmetic and Investigational Dermatology · 2026-07 · Volume 19 · 1-5

DOI: 10.2147/ccid.s599596 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-07. Verfasst von Lang Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jianghan University School of Medicine, Wuhan, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Bullous pemphigoiddupilumabomalizumabrituximab

Autor:innen und Institutionen

  • Jianghan University School of Medicine, Wuhan, People's Republic of China.
  • Department of Dermatology, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Department of Dermatology, Wuhan No.1 Hospital, Wuhan, People's Republic of China.

ORCID-Profile: Quanhong Zhang, Yue Zhu, Jinbo Chen

Zitieren

APA

Yu, L., Hu, G., Zhang, Q., Zhu, Y., Chen, L., & Chen, J. (2026). Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-5. https://doi.org/10.2147/ccid.s599596

Vancouver

Yu L, Hu G, Zhang Q, Zhu Y, Chen L, Chen J. Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-5. doi:10.2147/ccid.s599596

BibTeX
@article{Yu2026,
  author = {Yu, Lang and Hu, Gang and Zhang, Quanhong and Zhu, Yue and Chen, Liuqing and Chen, Jinbo},
  title = {Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab},
  journal = {Clinical, Cosmetic and Investigational Dermatology},
  year = {2026},
  volume = {Volume 19},
  pages = {1--5},
  doi = {10.2147/ccid.s599596}
}
Kostenlos starten →